AbbVie Inc. (ABBV) Net Income
The annual net income for AbbVie Inc. (ABBV) is $4.23 Billion with a year-over-year change of (1.22%). Net income represents the company's bottom line profit after all expenses, taxes, and interest.
Annual Net Income (TTM)
$4.23B
$4.23 Billion
Year-over-Year Change
(1.22%)
vs. $4.28B prior year
Net Income CAGR
(6.74%)
5 Year compound annual growth rate
Net Income CAGR (Compound Annual Growth Rate)
1 Year
(13.26%)
3 Year
(21.71%)
5 Year
(6.74%)
10 Year
(4.00%)
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
Annual Net Income History
| Year | Net Income | YoY Change | % Change |
|---|---|---|---|
| 2025 | $4.23B | ($52.00M) | (1.22%) |
| 2024 | $4.28B | ($585.00M) | (12.03%) |
| 2023 | $4.86B | ($6.97B) | (58.91%) |
| 2022 | $11.84B | +$294.00M | +2.55% |
| 2021 | $11.54B | +$6.93B | +150.04% |
| 2020 | $4.62B | ($3.27B) | (41.44%) |
| 2019 | $7.88B | +$2.19B | +38.60% |
| 2018 | $5.69B | +$378.00M | +7.12% |
| 2017 | $5.31B | ($644.00M) | (10.82%) |
| 2016 | $5.95B | +$809.00M | +15.73% |
Net Income Growth Summary
TTM Growth
(13.26%)
3-Year Avg Growth
(21.71%)
5-Year Avg Growth
(6.74%)
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael